Skip to main content


We offer a bioinformatics-led approach to humanise existing antibodies against challenging membrane proteins, before using our proprietary SLIM™ display platform for affinity maturation. Then our automated gene editing platform can support your validation campaigns, for example through the generation of clonal knock-out cell lines or complex disease models.

We put a strong emphasis on communication with our partners, who remain in direct contact with both the project manager and scientific team throughout the project.

Antibody Humanisation and Affinity Maturation

OXGENE conducts bioinformatic analysis, codon optimisation, DNA synthesis, and antibody production and purification in house. Our software assisted design process is based on in depth expertise and experience. It generates a custom-picked selection of variants using our comprehensive vector toolkit and proprietary antibody template database.

We then use our integrated MHC class II binding prediction and manufacturability analysis to identify liabilities to remove during the process. The variants generated are expressed and purified using OXGENE’s automated high throughput platform, in our proprietary HEK293 EBNA suspension cell line.

We can then use our SLIM display platform to screen affinity maturation libraries to improve the affinity and biophysical properties of a low affinity antibody.

SLIM™ Display

OXGENE has developed a novel CHO-based mammalian display antibody discovery technology targeting membrane proteins. We construct and routinely screen synthetic antibody libraries above 1E10 variants, up to 100-fold higher than typical mammalian display techniques. We achieve our large library size by the innovative packaging of antibody libraries into viral particles, which we then use to infect CHO cells with 90% integration efficiency. We use this cutting-edge method to discover novel binders and generate therapeutic leads for CAR-T and other antibody based therapeutics.

These major advantages complement other key features, including presentation of the proteins in their native configuration on the cell surface - including correct glycosylation - to avoid the need for antigen purification or the humanisation of any leads we discover. We also use the CHO cell line to accelerate the development of these antibodies as biotherapeutics.


View our most recent mammalian display poster.



Complex gene edits and target validation

Following a SLIM display discovery or affinity maturation campaign, we can also deploy our automated gene editing platform to support your validation campaigns, for example through the generation of clonal knock-out cell lines or complex disease models.

With the support of our automated gene editing platform, our in-house experts generate clonal cell lines modelling complex disease scenarios, including double knock-outs, conditional knock-outs, knock-ins, gene fusions and chromosomal rearrangements.

We’ve also optimised our automated gene editing platform to accommodate high throughput edits of inducible Pluripotent Stem Cells (iPSCs). These are a particularly powerful tool for disease modelling and drug discovery, but can be challenging to work with, as they differentiate in response to cellular stress, and exhibit notoriously low editing efficiency. However, we’ve optimised our gene editing workflow to achieve a careful balance between cellular stability and editing efficiency to deliver reliably edited iPSC lines.



Talk to our team about our SLIM™ display
and antibody engineering platforms

Transient lentiviral expression systems

Lentiviral libraries and small scale production to optimise vector design for pre-clinical testing